Application note: Distinguishing cell types by phenotypic profiling
Posted: 24 January 2018 | Alexander Schreiner (PerkinElmer), Karin Böttcher (PerkinElmer), Mandy Malle (PerkinElmer) | No comments yet
Describing how a single nuclear stain can enable phenotypic profiling for new and additional perspectives on assays at no extra cost.
The promise of high-content screening is the acceleration of discovery by extracting as much relevant information as possible from cells. Nevertheless, a large percentage of high-content screens analyse only a small number of image-based properties.
As nearly all screening approaches require a nuclear counterstain to facilitate segmentation, phenotypic profiling of the nuclei can offer new and additional perspectives on assays at no extra cost.
This study shows how a single nuclear stain can enable phenotypic profiling and how phenotypic profiles can be used to distinguish up to seven different cell types, without further staining or phenotypic markers. Such methods could be applied to other fluorescent labels, opening up new horizons for unbiased drug discovery and disease research.
This application note describes how to:
- Distinguish cell types based exclusively on nuclear staining
- Generate detailed phenotypic profiles using texture and advanced morphology parameters
Apply machine learning classification tools and visualisation tools, such as Principle Component Analysis, to better understand multiparametric data sets
This application note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- Global high-content screening market set to be worth $2.52bn by 2030
- Assays for protein degradation therapeutics to accelerate undruggable proteome discoveries
- Lab automation market set to increase at CAGR of seven percent
- Brochure: Biologics workflow solutions brochure
- Brochure: Viral research solutions
Related topics
Assays, Drug Discovery, Drug Discovery Processes, Screening, Translational Science
Related organisations
PerkinElmer